Karen WagnerBoard Member
Dr. Karen Wagner is a senior executive and entrepreneur with close to 20 years’ experience in the biopharmaceutical industry. Karen is General Partner at Ysios Capital Partners and her main role at Ysios is to identify and manage therapeutic investments.
In addition to Xeltis, Karen serves on the Boards of Aelix Therapeutics and Vivet Therapeutics and is an observer on the Board of Minoryx Therapeutics. She holds a master’s degree in Molecular Biology and a PhD in Cell Biology.